Canadian Court Upholds Pfizer's Norvasc Patent

Law360, New York (April 17, 2008, 12:00 AM EDT) -- A Canadian federal court has upheld the validity of a Pfizer Inc. patent covering the active ingredient in blood pressure treatment Norvasc.

In a ruling Thursday, Judge Roger T. Hughes of the Canadian Federal Court prohibited Canada’s Minister of Health from approving Pharmascience Inc.'s generic version of Norvasc until Pfizer’s patent expires.

The patent-in-suit, Canadian Patent Number 1,321,393, covers amlodipine besylate, the active ingredient in Norvasc, and expires in August 2010, Pfizer said.

Judge Hughes said Montreal-based Pharmscience’s generic tablets could not be approved by the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.